The metformin, an antidiabetic drug widely used throughout the world to treat type II diabetes, is also effective in combating certain types of cancer. That is the conclusion reached by two Spanish studies led by the coordinator of the Translational Research Unit of the Catalan Institute of Oncology (ICO) of Gerona, Dr. Javier Menéndez.
Previous studies had revealed that the incidence of breast cancer and deaths from this condition were lower in diabetic patients who had been treated with metformin.
Therefore, from the ICO launched a study to study this association and demonstrate that metformin has the ability to inhibit certain cellular activity typical of one of the most aggressive types of breast cancer, known as HER2 positive, a cancer of poor prognosis, with a tendency to recur and that, in the long term, does not respond to the available treatments.This finding reinforces the thesis that cancer originates as a result of metabolic alterations of cells
This finding reinforces the thesis that cancer originates as a result of metabolic alterations of cells, similar to those that cause pathologies such as diabetes or obesity, so it could contribute to developing alternatives for the treatment of cancer from the point of view of cancer. metabolic view.
The effect that metformin causes in the evolution of breast cancer has served to study its effectiveness in other oncological processes, such as lung cancer and ovarian cancer, opening a new range of possibilities in the fight against cancer.
The studies, directed by Dr. Javier Menéndez, and published in C journalsell Cycle Y Annals of Oncology have found that metformin, in addition to inhibiting HER2 + tumor cells, causes a survival effect at the level of cardiac cells.